10-K: Surmodics Reports Fiscal 2024 Results Amidst Pending Merger, Faces Revenue Headwinds in 2025

Surmodics' fiscal year 2024 saw a revenue decrease and a net loss, with the company anticipating further revenue declines in 2025 due to reduced SurVeil DCB sales, all while navigating a pending merger.

Summary

• Surmodics reported a revenue of $126.1 million for fiscal year 2024, a 5% decrease compared to the previous year's $132.6 million.
• The company experienced a net loss of $11.5 million in fiscal 2024, and expects to continue incurring net losses in the future.
• Medical Device segment revenue decreased by 8%, primarily due to lower SurVeil DCB license fee revenue, despite growth in product sales and performance coating royalties.
• SurVeil DCB license fee revenue decreased significantly from $29.6 million in fiscal 2023 to $5.1 million in fiscal 2024, and is expected to decline further in fiscal 2025.
• Product sales in the Medical Device segment increased by 34%, driven by SurVeil DCB and Pounce thrombectomy devices.
• Performance coating royalties and license fee revenue increased by 14%, driven by the Serene hydrophilic coating technology.
• The In Vitro Diagnostics (IVD) segment saw a 7% revenue increase, driven by product revenue and R&D services.
• Product gross margin decreased to 55.1% in fiscal 2024, down from 58.8% in fiscal 2023, primarily due to SurVeil DCB production inefficiencies.
• Research and development expenses decreased by 18% year-over-year, primarily due to lower SurVeil DCB and thrombectomy platform R&D costs.
• Selling, general, and administrative expenses increased by 10%, driven by merger-related charges and increased sales compensation.
• The company expects a decline in SurVeil DCB product revenue by approximately $5.0 million in fiscal 2025 compared to fiscal 2024.
• Surmodics anticipates completion of the TRANSCEND pivotal clinical trial in the second quarter of fiscal 2025, with no further recognition of SurVeil DCB license fee revenue after March 31, 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant challenges. While there are some positive developments in product sales and technology, the overall financial performance is weak, and the future outlook is uncertain due to the pending merger and expected revenue declines. The company is facing significant headwinds and risks.

Positives

• Medical Device product sales increased by 34%, driven by SurVeil DCB and Pounce thrombectomy devices.
• Performance coating royalties and license fee revenue grew by 14%, primarily due to the Serene hydrophilic coating technology.
• The In Vitro Diagnostics (IVD) segment saw a 7% revenue increase, driven by product revenue and R&D services.
• The company completed limited market evaluations for the Pounce LP Thrombectomy System and the Sublime microcatheter, and the products were commercially launched.
• The Pounce XL Thrombectomy System received FDA 510(k) regulatory clearance in the fourth quarter of fiscal 2024.

Negatives

• Surmodics experienced a 5% decrease in total revenue year-over-year.
• The company reported a net loss of $11.5 million for fiscal 2024.
• SurVeil DCB license fee revenue decreased by 83% year-over-year.
• The company expects a $5.0 million decline in SurVeil DCB product revenue in fiscal 2025.
• Product gross margin decreased to 55.1% in fiscal 2024, down from 58.8% in fiscal 2023.
• The company expects product gross profit and product gross margin to decline in fiscal 2025.
• The company expects no further recognition of SurVeil DCB license fee revenue after March 31, 2025.

Risks

• The pending merger with BCE Parent, LLC is subject to various closing conditions, including regulatory approval, and may not be completed.
• The company faces risks related to the consummation of the merger, including potential termination fees and the impact on business relationships.
• The company is subject to restrictions on its business operations due to the merger agreement.
• The company is experiencing employee attrition due to uncertainty related to the merger.
• The company relies on a small number of significant customers, including Abbott and Medtronic, which exposes it to risks affecting those customers.
• The company anticipates a decline in SurVeil DCB revenue in fiscal 2025 and may not achieve profitability.
• The company faces intense competition in the medical device market.
• The company's credit agreement contains covenants that restrict its business and financing activities.
• The company may face product liability claims related to clinical trials or the use of its products.
• The company's revenue will be harmed if it experiences disruptions in its supply chain.
• The company depends upon key personnel and may not be able to attract or retain qualified personnel in the future.
• Security breaches and other disruptions could compromise the company's information and expose it to liability.
• The company may not be able to obtain, maintain or protect proprietary rights necessary for the commercialization of its technologies.
• The company may become involved in expensive and unpredictable patent litigation or other intellectual property proceedings.
• The company's revenue will be harmed if it experiences disruptions in its supply chain.
• The company's stock price has been volatile and may continue to be volatile.

Future Outlook

Surmodics anticipates a decline in SurVeil DCB product revenue and license fee revenue in fiscal 2025, and expects to continue incurring net losses. The company also expects product gross profit and product gross margin to decline in fiscal 2025. The company expects to complete the TRANSCEND pivotal clinical trial in the second quarter of fiscal 2025, with no further recognition of SurVeil DCB license fee revenue after March 31, 2025.

Management Comments

• The company believes its strategy of developing its own medical device products has increased, and will continue to increase, its relevance in the medical device industry.
• The company believes its thrombectomy systems are attractive first-line treatment options for interventionalists due to their ease of use, intuitive design, and performance.
• The company believes its Sublime device portfolio is uniquely positioned to lead the market for dedicated devices that facilitate a radial-to-peripheral approach.

Industry Context

The medical device industry is highly competitive, with companies seeking to differentiate their products through new enhancements. Surmodics faces competition from larger OEM suppliers and medical device companies. The company's performance coating technologies compete with technologies developed by other companies, and many medical device manufacturers have developed internal competency in performance coatings. The company's vascular intervention products compete with global leaders in the vascular medical device market.

Comparison to Industry Standards

• The U.S. DCB market, where Surmodics' SurVeil DCB competes, is dominated by three companies with over 90% market share, indicating a challenging competitive landscape.
• Surmodics' SurVeil DCB is not compatible with a 0.018 guidewire, which represents over 40% of the U.S. DCB market and is growing at a higher rate, potentially limiting its market penetration.
• The company's thrombectomy devices compete with existing treatments such as catheter-directed thrombolysis and surgical embolectomy, requiring them to demonstrate superior efficacy and cost-effectiveness.
• Surmodics' radial access devices compete with other devices used for peripheral interventions, requiring them to demonstrate improvements in patient outcomes through reduced invasiveness.
• The company's performance coating technologies compete with those developed by other companies, as well as internal efforts by large medical device manufacturers, requiring them to offer a high value-added approach.

Legal Proceedings

• In July 2024, two of the company's shareholders filed separate lawsuits in New York State court against the company and its board, alleging that the proxy statement relating to the merger was materially misleading and contained material omissions.

Stakeholder Impact

• Shareholders face uncertainty due to the pending merger and potential for reduced returns.
• Employees are experiencing uncertainty and attrition due to the merger.
• Customers may be affected by potential disruptions in the company's operations due to the merger.
• Suppliers may be affected by potential changes in the company's business relationships due to the merger.
• Creditors face risks related to the company's financial performance and potential for default under its credit agreement.

Next Steps

• The company plans to initiate limited market evaluations of the Pounce XL Thrombectomy System in the first half of fiscal 2025.
• The company expects to complete the TRANSCEND pivotal clinical trial in the second quarter of fiscal 2025.
• The company and Parent expect to consummate the Merger in the company's second fiscal quarter ending March 31, 2025, subject to customary closing conditions, including required regulatory approval.

Key Dates

Keywords

Surmodics, Medical Device, In Vitro Diagnostics, Vascular Intervention, Drug-Coated Balloon, Thrombectomy, Radial Access, Performance Coatings, Merger, Abbott, Medtronic, FDA, Revenue, Profitability, Clinical Trials